Corcept reports eight-year response to relacorilant combination in vulvar cancer patient
CORT•Corcept Therapeutics said a patient with metastatic vulvar cancer had disease control for approximately eight years on relacorilant combined with nab-paclitaxel; the patient remained on treatment with stable disease as of July 2026.




